跳至主要内容
临床试验/ISRCTN13297409
ISRCTN13297409已完成1 期

Single Dose Crossover Comparative Bioavailability Study under Fasting Conditions and Food Effect Study of Sildenafil 100 mg Oral Films Versus Viagra® (Sildenafil) Tablets in Healthy Male Volunteers

IBSA Institut Biochimique S.A.0 个研究点目标入组 45 人开始时间: 2018年9月4日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
45

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Male

入选标准

  • 1. Aged 18-45 years
  • 2. BMI of 18.5 - 30.0 kg/m²
  • 3. Non-smoker or ex-smoker
  • 4. No clinically significant diseases or findings upon physical examination and/or clinical laboratory evaluations (hematology, general biochemistry, lipid profile, ECG and urinalysis)
  • 5. Provided signed informed consent

排除标准

  • 1. Presence or history within 28 days of any tongue piercings
  • 2. Presence of partials, braces or dentures
  • 3. History of significant hypersensitivity to sildenafil or related products (including excipients of formulations)
  • 4. History of severe hypersensitivity reactions to any drugs
  • 5. Significant gastrointestinal, liver or kidney disease, or any other conditions known to:
  • 5.1. Interfere with the absorption, distribution, metabolism or excretion of drugs
  • 5.2. Potentiate or predispose to undesired effects such as severe liver failure, acute or chronic liver dysfunction or cholestatic jaundice
  • 6. History of significant gastrointestinal, liver or kidney disease that may have affected drug bioavailability
  • 7. Significant cardiovascular, pulmonary, hematological, neurological, psychiatric, endocrine, immunological or dermatological disease
  • 8. Suicidal tendencies, severe depression, state of confusion or other clinically relevant psychiatric diseases
  • 9. History of or disposition to seizures
  • 10. Presence of out-of-range cardiac interval on the screening ECG or other clinically significant ECG abnormalities
  • 11. Use of organic nitrate medications in the previous 28 days
  • 12. History of vision or hearing problems related to the PDE5 inhibitor pharmacological class
  • 13. Presence or history of priapism
  • 14. Anatomical deformation of the penis
  • 15. History of ophthalmological disease, such as non-arteritic anterior ischemic optic neuropathy or retinitis pigmentosa
  • 16. Known presence of rare hereditary problems of:
  • 16.1. Galactose and/or lactose intolerance
  • 16.2. Lactase deficiency
  • 16.3. Glucose-galactose malabsorption
  • 17. Maintenance therapy with any drug or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol (acute or chronic))
  • 18. Positive screening for alcohol and/or drug abuse
  • 19. Use of enzyme modifying drugs in the previous 28 days, including:
  • 19.1. Strong inhibitors of CYP enzymes (e.g. cimetidine, fluoextine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals)
  • 19.2. Strong inducers of CYP enzymes (e.g. barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and St Johns Wort)
  • 20. History of tuberculosis and/or prophylaxis for tuberculosis
  • 21. Positive results to the following tests:
  • 21.1. HIV Ag/Ab Combo
  • 21.2. Hepatitis B surface antigen (HBsAG (B) (hepatitis B))
  • 21.3. Hepatitis C Virus (HCV (C))
  • 22. Taken sildenafil in the previous 28 days
  • 23. Donated 500 ml or more of blood in the previous 56 days

研究者

发起方
IBSA Institut Biochimique S.A.

相似试验